When you have a brand with as much promise as Farxiga, you need someone at the helm with the drive and vision to help it reach its full potential. And that person is senior director of marketing for Farxiga, Allison Garrity. When Garrity joined the Farxiga team, the established AstraZeneca brand already had a strong legacy in type 2 diabetes (T2D), but momentum had stalled, teams needed to be rebuilt, and – the biggest challenge of all – Farxiga had to revolutionize care again, this time with indications in heart failure (HF) and chronic kidney disease (CKD).
Aeglea BioTherapeutics announced on April 11 promising Phase III results for patients diagnosed with arginase 1 deficiency (ARG1-D), a rare hereditary metabolic disorder. Aeglea said on April 12 the company had submitted its first-ever Biologics License Application (BLA) to the U.S. Food and Drug Administration for the drug.
Following the ongoing trend in the pharmaceutical industry, bluebird bio orchestrated a restructuring that includes saving financially and cutting staff. The restructuring is designed to prolong the company’s budget as bluebird bio awaits decisions from the U.S. Food and Drug Administration (FDA).
Risk of type 2 diabetes rises after COVID; organ transplant from donors who had COVID likely safeCoronavirus Disease (COVID-19) Pandemic, COVID-19 Severe Complications, COVID-19 Studies, JAMA Psychiatry, Medical Journals, Neuropsychiatric Diseases, Organ Transplantation, R&D, Reuters, The Lancet Diabetes & Endocrinology, Type 2 Diabetes, U.S. Department of Veterans Affairs
People may be at increased risk for developing diabetes for up to a year after a diagnosis of COVID-19, according to two studies. Additionally, organ donation from dying donors with current or previous COVID-19 infection is likely safe, transplant teams from the United States and Italy will report at the April 2022 European Congress of Clinical Microbiology & Infectious Diseases meeting.
Studies Suggest Links Between COVID-19 and Diabetes, Pregnancy Risks and DementiaClinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Studies, Dementia, Diabetes, Heart Problems, JAMA Internal Medicine, Nature Medicine, Neurological Conditions, Pregnancies, R&D, The Lancet Diabetes & Endocrinology, Type 2 Diabetes, University of Iowa, University of Rochester Medical Center
The most obvious risks from COVID-19 are hospitalization and death. But study after study shows the disease comes with an increased risk of a number of health problems, including diabetes.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
AREA 23 and Hip Hop Public Health Launch “Lil Sugar,” Exposing the Many Hidden Forms of Sugar in Food ProductsCampaign Launches, Campaigns, Children, Data, Food, Health Education, Healthcare Communications Agencies, Healthcare Communications Networks, Marketing & Advertising, Nonprofit, Obesity, Sugar, Type 2 Diabetes
AREA 23 (an IPG Health company) launched the multi-platform campaign “Lil Sugar” in collaboration with global non-profit organization Hip Hop Public Health to raise awareness about the hidden sugars in many foods.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland further defined the association between comorbidities and poor outcomes with Covid-19.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.